319 related articles for article (PubMed ID: 16567357)
1. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
[TBL] [Abstract][Full Text] [Related]
2. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D
Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
4. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept.
Cole JC; Li T; Lin P; MacLean R; Wallenstein GV
Rheumatology (Oxford); 2008 Jul; 47(7):1044-50. PubMed ID: 18487628
[TBL] [Abstract][Full Text] [Related]
5. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life.
Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS
J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505
[TBL] [Abstract][Full Text] [Related]
6. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
[TBL] [Abstract][Full Text] [Related]
7. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
[TBL] [Abstract][Full Text] [Related]
8. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
Shergy WJ
Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
10. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis.
Wells G; Li T; Maxwell L; Maclean R; Tugwell P
Ann Rheum Dis; 2008 Feb; 67(2):260-5. PubMed ID: 17846044
[TBL] [Abstract][Full Text] [Related]
11. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
[TBL] [Abstract][Full Text] [Related]
12. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
[TBL] [Abstract][Full Text] [Related]
13. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.
Weinblatt M; Schiff M; Goldman A; Kremer J; Luggen M; Li T; Chen D; Becker JC
Ann Rheum Dis; 2007 Feb; 66(2):228-34. PubMed ID: 16935912
[TBL] [Abstract][Full Text] [Related]
14. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale.
Wells G; Li T; Tugwell P
Ann Rheum Dis; 2010 Oct; 69(10):1768-73. PubMed ID: 20610444
[TBL] [Abstract][Full Text] [Related]
15. Role of abatacept in the management of rheumatoid arthritis.
Nogid A; Pham DQ
Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
[TBL] [Abstract][Full Text] [Related]
16. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
Massarotti EM
Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
[TBL] [Abstract][Full Text] [Related]
17. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial.
Kremer JM; Dougados M; Emery P; Durez P; Sibilia J; Shergy W; Steinfeld S; Tindall E; Becker JC; Li T; Nuamah IF; Aranda R; Moreland LW
Arthritis Rheum; 2005 Aug; 52(8):2263-71. PubMed ID: 16052582
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists.
Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Li T; Oster G
J Rheumatol; 2008 Sep; 35(9):1745-53. PubMed ID: 18634164
[TBL] [Abstract][Full Text] [Related]
20. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.
Guyot P; Taylor PC; Christensen R; Pericleous L; Drost P; Eijgelshoven I; Bergman G; Lebmeier M
J Rheumatol; 2012 Jun; 39(6):1198-206. PubMed ID: 22505698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]